Open in Screener

ALNY

Alnylam Pharmaceuticals Inc

Feb 24 • 11:49AM ET

328.76

-0.59 -0.18 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMRN BIIB IONS SRPT ARWR NTLA CRSP EDIT

| Held by: VTI VO QQQ VUG VXF VOT IBB IWP CGGR IWF

Index	NDX	P/E	145.66	EPS (ttm)	2.26	Insider Own	0.90%	Shs Outstand	132.38M	Perf Week	-1.16%
Market Cap	43.60B	Forward P/E	29.49	EPS next Y	11.15	Insider Trans	-9.02%	Shs Float	131.43M	Perf Month	-8.16%
Enterprise Value	43.66B	PEG	0.35	EPS next Q	0.99	Inst Own	98.12%	Short Float	4.02%	Perf Quarter	-26.25%
Income	313.75M	P/S	11.74	EPS this Y	191.86%	Inst Trans	-4.13%	Short Ratio	3.39	Perf Half Y	-27.65%
Sales	3.71B	P/B	55.15	EPS next Y	63.95%	ROA	6.73%	Short Interest	5.28M	Perf YTD	-17.32%
Book/sh	5.96	P/C	14.99	EPS next 5Y	84.85%	ROE	73.28%	52W High	495.55 -33.66%	Perf Year	32.07%
Cash/sh	21.93	P/FCF	93.69	EPS past 3/5Y	- -	ROIC	8.98%	52W Low	205.87 59.69%	Perf 3Y	73.23%
Dividend Est.	-	EV/EBITDA	78.35	Sales past 3/5Y	52.98% 49.77%	Gross Margin	81.64%	Volatility	4.31% 3.81%	Perf 5Y	116.88%
Dividend TTM	-	EV/Sales	11.76	EPS Y/Y TTM	209.06%	Oper. Margin	13.51%	ATR (14)	13.47	Perf 10Y	466.64%
Dividend Ex-Date	-	Quick Ratio	2.71	Sales Y/Y TTM	65.19%	Profit Margin	8.45%	RSI (14)	40.78	Recom	1.60
Dividend Gr. 3/5Y	- -	Current Ratio	2.76	EPS Q/Q	310.87%	SMA20	-1.55%	Beta	0.36	Target Price	463.12
Payout	0.00%	Debt/Eq	3.76	Sales Q/Q	84.95%	SMA50	-10.28%	Rel Volume	0.36	Prev Close	329.35
Employees	2500	LT Debt/Eq	3.43	Earnings	Feb 12 BMO	SMA200	-15.53%	Avg Volume	1.56M	Price	328.76
IPO	May 28, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-29.06% -4.53%	Trades		Volume	215,707	Change	-0.18%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$527
Jan-07-26	Resumed	Oppenheimer	Outperform	$500
Aug-04-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Aug-04-25	Upgrade	Oppenheimer	Perform → Outperform	$490
Jul-30-25	Resumed	Raymond James	Outperform	$370
Jul-21-25	Initiated	Truist	Buy	$385
Mar-31-25	Initiated	Redburn Atlantic	Buy	$353
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight	$280 → $328
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy	$198 → $370
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243

Show Previous Ratings

Today 11:43AM	GSK Strikes $1 Billion China RNA Deal (GuruFocus.com)
Feb-23-26 10:00AM	Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-20-26 04:08AM	Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge (Insider Monkey)
Feb-19-26 12:01AM	Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth (Insider Monkey)
Feb-17-26 12:09PM	RNA-targeting small molecules: a new frontier of drug discovery (Pharmaceutical Technology) +5.79%
01:21AM	Loading…
Feb-14-26 01:21AM	Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? (Insider Monkey)
Feb-13-26 04:30PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +5.79%
10:19AM	ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down (Zacks)
Feb-12-26 04:31PM	Alnylam Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
04:06PM	Alnylam Pharmaceuticals Inc (ALNY) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
10:00AM	Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings (Zacks)
09:10AM	Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates (Zacks)
08:22AM	Alnylam: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
12:57PM	Loading…
Feb-11-26 12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
Feb-10-26 10:00AM	Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-09-26 09:15AM	Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-06-26 08:34AM	Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Don't? (Zacks)
Feb-05-26 10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? (Zacks) -5.89%
Jan-31-26 09:35AM	Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth (Insider Monkey)
Jan-29-26 09:55PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
04:09PM	Phillip Allen Sharp Improved Human Health With Breakthroughs (Investor's Business Daily)
02:27PM	Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy (Insider Monkey)
08:00AM	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-28-26 05:04AM	Should You Buy Alnylam Pharmaceuticals Before Feb. 12? (Motley Fool)
Jan-27-26 08:38AM	Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression (Insider Monkey)
Jan-14-26 08:02AM	JPM26: 2025 a breakout year for rare disease biotechs (Clinical Trials Arena)
Jan-12-26 07:03PM	Alnylam Pharmaceuticals CEO on Development Goals, Profitability (Bloomberg) -6.87%
04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily)
02:42PM	Loading…
02:42PM	Alnylam Pharmaceuticals Unveils Alnylam 2030 as Amvuttra Drives Breakout Growth at JPMorgan Conf. (MarketBeat)
01:33PM	Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale (Benzinga)
12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga)
11:15AM	Equity Indexes Recover Early Losses as Precious Metals Reach New Record Highs (Barchart)
10:18AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
06:24AM	AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations (BioPharma Dive)
Jan-11-26 05:00PM	Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact (Business Wire)
Jan-09-26 09:09PM	Walmart To Join Nasdaq 100 on Jan. 20 as AstraZeneca Exits (Bloomberg) -6.87%
11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
Jan-08-26 08:00AM	Biotech Stocks' Dark Winter Is Over. What That Means For Investors. (Investor's Business Daily) -5.47%
Jan-07-26 11:02AM	Healthcare and technology stocks are driving up the Nasdaq (MarketWatch)
Jan-05-26 09:15AM	Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-30-25 11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
Dec-19-25 06:18AM	Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q3 (Insider Monkey)
Dec-18-25 05:15AM	Alnylam plans $250m investment in Norton manufacturing facility, US (Pharmaceutical Technology)
Dec-17-25 08:00AM	Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics (Business Wire)
Dec-15-25 12:15PM	MicroStrategy retains place in key index despite delisting threats (TheStreet)
10:05AM	Lululemon Set to Exit Nasdaq 100 as Index Adds New Members (GuruFocus.com)
09:11AM	Western Digital stock rises after inclusion in Nasdaq-100 Index (Investing.com)
07:03AM	200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party (GuruFocus.com)
Dec-13-25 11:04AM	Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut (MarketWatch)
Dec-12-25 08:21PM	Bitcoin hoarding company Strategy remains in Nasdaq 100 (Reuters)
08:30AM	Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options (Zacks)
Dec-11-25 07:00AM	Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 (Business Wire)
Dec-07-25 02:45AM	Is Alnylam Pharmaceuticals a Millionaire Maker? (Motley Fool)
Dec-05-25 04:34PM	The S&P 500 Is Due to Rebalance on Friday. What Could Change. (Barrons.com) -6.13%
Dec-03-25 08:00AM	Alnylam Pharmaceuticals Announces Changes to Board of Directors (Business Wire)
Dec-02-25 08:11AM	These Stocks Could Join the S&P 500 in Rebalancing (Barrons.com)
08:02AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Dec-01-25 05:09PM	These Stocks Could Join the S&P 500 in Rebalancing (Barrons.com)
03:47PM	CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing (Barrons.com)
Nov-22-25 08:00AM	S&P 500 Retailer Leads Five Resilient Stocks After Nvidia-Led Market Sell-Off (Investor's Business Daily)
Nov-20-25 01:39PM	High-Flying Biotech Stock Sets Up After 96% Pop; Profitability In Sight As Key Drug Sales Double (Investor's Business Daily)
01:35PM	Highflying Biotech Stock Sets Up After 96% Pop; Annual Profit In Sight As Key Drug Sales Double (Investor's Business Daily)
Nov-18-25 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-13-25 09:07AM	Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook (Insider Monkey)
03:00AM	RNAi looked doomed to fail until Alnylams science chief found a way (Pharma Voice)
Nov-11-25 05:40AM	Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money (Motley Fool)
Nov-08-25 04:57PM	New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM (Business Wire)
Nov-04-25 11:28AM	Top 20 biopharma companies Q3 2025 market cap up 4% despite headwinds (Pharmaceutical Technology)
08:00AM	Alnylam to Webcast Presentations at Upcoming November Investor Conferences (Business Wire)
Oct-31-25 10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)
08:04AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Oct-30-25 04:24PM	Alnylam Pharmaceuticals Inc (ALNY) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -6.65%
04:19PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
10:30AM	Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
09:15AM	Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates (Zacks)
08:16AM	Alnylam: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Oct-29-25 01:47PM	Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect (Zacks)
11:27AM	Amgen's Q3 Earnings in the Cards: Here's What to Expect (Zacks)
Oct-28-25 04:21PM	These Are The 5 Best Stocks To Buy Now Or Watch (Investor's Business Daily)
11:52AM	Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
09:15AM	Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS (Zacks)
Oct-27-25 12:44PM	ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
10:00AM	Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-24-25 09:56AM	REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? (Zacks)
Oct-23-25 02:54PM	Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
10:19AM	IQVIA Gears Up to Report Q3 Earnings: What's in the Cards? (Zacks)
10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:05AM	RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised (Zacks)
Oct-22-25 11:04AM	NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board (Zacks)
Oct-21-25 09:34AM	Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis (Zacks)
09:30AM	NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients (Zacks)
Oct-20-25 12:20PM	Why Alnylam (ALNY) Might be Well Poised for a Surge (Zacks)
Oct-18-25 09:05AM	Alnylam price target raised to $535 from $459 at Truist (TipRanks)
08:00AM	S&P 500's Walmart In Buy Zone, Leads Five Stocks Near Buy Points (Investor's Business Daily)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garg Pushkal	EVP Chief R&D	Feb 13 '26	Sale	310.08	2,242	695,201	24,848	Feb 17 07:28 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 13 '26	Sale	310.08	6,958	2,157,542	85,662	Feb 17 07:27 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 13 '26	Sale	310.08	1,959	607,448	31,769	Feb 17 07:27 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 17 '26	Sale	331.96	2,041	677,532	21,264	Feb 17 07:26 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 13 '26	Sale	310.08	1,959	607,448	23,305	Feb 17 07:26 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 13 '26	Sale	310.08	2,242	695,201	59,802	Feb 17 07:26 PM
Fitzgerald Kevin Joseph	Officer	Feb 17 '26	Proposed Sale	331.96	2,041	677,532		Feb 17 04:10 PM
Garg Pushkal	EVP Chief R&D	Jan 12 '26	Sale	362.87	1,510	547,929	22,511	Jan 14 04:23 PM
Greenstreet Yvonne	Chief Executive Officer	Jan 12 '26	Sale	362.86	9,577	3,475,157	78,411	Jan 14 04:23 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Jan 12 '26	Sale	362.87	2,780	1,008,766	57,465	Jan 14 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Jan 12 '26	Sale	362.87	1,510	547,927	29,728	Jan 14 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jan 13 '26	Sale	370.33	2,290	848,065	21,264	Jan 14 04:21 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jan 12 '26	Sale	362.87	1,510	547,927	23,554	Jan 14 04:21 PM
Fitzgerald Kevin Joseph	Officer	Jan 13 '26	Proposed Sale	369.10	2,290	845,239		Jan 13 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 26 '25	Option Exercise	106.40	4,697	499,756	70,106	Dec 01 04:10 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 17 '25	Option Exercise	119.13	8,161	972,220	33,392	Nov 19 04:05 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 17 '25	Sale	452.18	12,128	5,483,990	21,264	Nov 19 04:05 PM
Fitzgerald Kevin Joseph	Officer	Nov 17 '25	Proposed Sale	449.00	12,128	5,445,472		Nov 17 04:04 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 12 '25	Option Exercise	115.94	15,650	1,814,393	81,059	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 13 '25	Option Exercise	119.13	10,000	1,191,300	75,409	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 12 '25	Sale	453.69	15,650	7,100,322	65,409	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 13 '25	Sale	451.27	10,000	4,512,682	65,409	Nov 14 04:13 PM
Greenstreet Yvonne	Officer	Nov 12 '25	Proposed Sale	453.10	25,650	11,621,956		Nov 12 04:03 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Oct 02 '25	Sale	452.05	3,821	1,727,284	54,052	Oct 03 05:14 PM
Greenstreet Yvonne	Chief Executive Officer	Oct 02 '25	Sale	452.05	8,924	4,034,085	65,409	Oct 03 05:14 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Oct 02 '25	Sale	452.05	1,405	635,126	27,438	Oct 03 05:14 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Oct 02 '25	Sale	452.05	2,441	1,103,451	25,231	Oct 03 05:13 PM
Garg Pushkal	EVP Chief R&D	Oct 03 '25	Sale	451.48	3,022	1,364,387	20,221	Oct 03 05:12 PM
Garg Pushkal	EVP Chief R&D	Oct 02 '25	Sale	452.05	2,937	1,327,675	23,243	Oct 03 05:12 PM
Garg Pushkal	Officer	Oct 03 '25	Proposed Sale	451.00	3,022	1,362,922		Oct 03 04:08 PM
Reitan Colleen F	Director	Sep 09 '25	Option Exercise	100.65	18,000	1,811,700	18,775	Sep 11 04:05 PM
Reitan Colleen F	Director	Sep 09 '25	Sale	467.60	18,000	8,416,730	775	Sep 11 04:05 PM
Reitan Colleen F	Director	Sep 09 '25	Proposed Sale	461.12	18,000	8,300,070		Sep 09 04:05 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Aug 29 '25	Sale	448.37	3,474	1,557,649	25,992	Sep 02 04:10 PM
Tanguler Tolga	Officer	Aug 29 '25	Proposed Sale	452.22	3,474	1,571,012		Aug 29 04:05 PM
Garg Pushkal	EVP Chief R&D	Aug 19 '25	Sale	458.41	1,455	666,987	20,221	Aug 19 05:28 PM
Garg Pushkal	EVP Chief R&D	Aug 18 '25	Sale	453.27	1,396	632,759	21,676	Aug 19 05:28 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Aug 18 '25	Sale	453.27	1,396	632,759	29,466	Aug 19 05:28 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Aug 18 '25	Sale	453.27	2,274	1,030,727	50,121	Aug 19 05:27 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 18 '25	Sale	453.27	6,979	3,163,346	56,221	Aug 19 05:27 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 18 '25	Sale	453.27	1,396	632,759	22,719	Aug 19 05:26 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Option Exercise	70.20	11,250	789,750	28,054	Aug 19 05:26 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Sale	450.00	11,250	5,062,500	16,804	Aug 19 05:26 PM
Garg Pushkal	Officer	Aug 19 '25	Proposed Sale	457.00	1,455	664,935		Aug 19 04:03 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Proposed Sale	450.00	11,250	5,062,500		Aug 18 04:08 PM
Ausiello Dennis A	Director	Aug 14 '25	Option Exercise	131.34	31,448	4,130,478	32,359	Aug 15 04:05 PM
Ausiello Dennis A	Director	Aug 14 '25	Sale	436.58	31,448	13,729,536	911	Aug 15 04:05 PM
Ausiello Dennis A	Director	Aug 14 '25	Proposed Sale	433.59	31,448	13,635,538		Aug 14 04:17 PM
Greenstreet Yvonne	Chief Executive Officer	May 30 '25	Option Exercise	118.46	31,640	3,748,149	80,588	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 02 '25	Option Exercise	118.73	19,297	2,291,057	68,245	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	May 30 '25	Sale	304.39	31,640	9,630,902	48,948	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 02 '25	Sale	306.00	19,297	5,904,882	48,948	Jun 03 04:10 PM
Greenstreet Yvonne	Officer	Jun 02 '25	Proposed Sale	303.10	19,297	5,848,824		Jun 02 04:08 PM
Greenstreet Yvonne	Officer	May 30 '25	Proposed Sale	304.39	31,640	9,630,902		May 30 04:18 PM
SHARP PHILLIP A	Director	May 30 '25	Proposed Sale	300.00	11,250	3,375,000		May 30 04:10 PM
BONNEY MICHAEL W	Director	May 15 '25	Option Exercise	131.21	11,250	1,476,112	28,054	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Sale	277.71	11,250	3,124,217	16,804	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Proposed Sale	269.53	11,250	3,032,212		May 15 04:03 PM
Reitan Colleen F	Director	Apr 16 '25	Sale	232.86	36	8,383	0	May 12 04:05 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 24 '25	Option Exercise	42.22	5,445	229,888	25,666	Mar 25 04:10 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 24 '25	Sale	300.00	5,445	1,633,500	20,221	Mar 25 04:10 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 21 '25	Sale	285.00	4,321	1,231,485	20,221	Mar 25 04:10 PM
PYOTT DAVID E I	Director	Mar 24 '25	Option Exercise	88.95	7,440	661,788	7,576	Mar 25 04:09 PM
PYOTT DAVID E I	Director	Mar 24 '25	Sale	299.00	7,440	2,224,560	136	Mar 25 04:09 PM
PYOTT DAVID E I	Director	Mar 24 '25	Proposed Sale	299.00	7,440	2,224,560		Mar 24 04:13 PM
Garg Pushkal	Officer	Mar 24 '25	Proposed Sale	300.00	5,445	1,633,500		Mar 24 04:06 PM
Garg Pushkal	Officer	Mar 21 '25	Proposed Sale	285.00	4,321	1,231,485		Mar 21 04:03 PM
SCHULMAN AMY W	Director	Mar 13 '25	Option Exercise	131.21	2,750	360,828	11,186	Mar 14 04:16 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 03 '25	Sale	243.73	1,911	465,772	14,345	Mar 05 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 04 '25	Sale	241.15	844	203,532	13,501	Mar 05 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 03 '25	Sale	243.78	471	114,820	28,011	Mar 05 04:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 03 '25	Sale	243.79	1,749	426,384	25,350	Mar 05 04:21 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 04 '25	Sale	241.05	808	194,766	24,542	Mar 05 04:21 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 03 '25	Sale	243.78	1,264	308,141	47,751	Mar 05 04:21 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 03 '25	Sale	243.79	3,877	945,165	98,635	Mar 05 04:20 PM
Fitzgerald Kevin Joseph	Officer	Mar 04 '25	Proposed Sale	241.09	844	203,479		Mar 04 04:07 PM
Garg Pushkal	Officer	Mar 04 '25	Proposed Sale	241.09	808	194,801		Mar 04 04:06 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '25	Option Exercise	0.00	5,921	0	87,447	Mar 03 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 28 '25	Sale	241.69	2,900	700,894	84,547	Mar 03 04:32 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '25	Option Exercise	0.00	1,908	0	34,694	Mar 03 04:31 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 28 '25	Sale	241.70	796	192,390	33,898	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '25	Option Exercise	0.00	1,667	0	14,858	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 28 '25	Sale	241.68	513	123,983	14,345	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 27 '25	Option Exercise	0.00	1,908	0	13,897	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 28 '25	Sale	241.69	935	225,977	12,962	Mar 03 04:31 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 28 '25	Sale	241.69	496	119,878	12,385	Mar 03 04:30 PM
Garg Pushkal	Officer	Mar 03 '25	Proposed Sale	246.18	973	239,533		Mar 03 04:09 PM
Fitzgerald Kevin Joseph	Officer	Mar 03 '25	Proposed Sale	246.18	1,171	288,277		Mar 03 04:09 PM

ASR Grupo Aeroportuario Del Sureste S.A. ADR daily Stock Chart

Peers: PAC OMAB DAL AAL UBER ALK LUV SAVE VALE ARMK

| Held by: IGF GII AVEM ORR JETS DFAE DFEM FRDM APIE DFAX

Index	-	P/E	18.95	EPS (ttm)	18.85	Insider Own	0.00%	Shs Outstand	27.70M	Perf Week	-5.65%
Market Cap	9.90B	Forward P/E	15.15	EPS next Y	23.59	Insider Trans	-	Shs Float	27.70M	Perf Month	5.65%
Enterprise Value	10.56B	PEG	4.33	EPS next Q	5.21	Inst Own	11.30%	Short Float	0.46%	Perf Quarter	20.66%
Income	565.51M	P/S	5.51	EPS this Y	-12.37%	Inst Trans	1.68%	Short Ratio	2.36	Perf Half Y	11.09%
Sales	1.80B	P/B	5.32	EPS next Y	12.33%	ROA	13.78%	Short Interest	0.13M	Perf YTD	10.47%
Book/sh	67.19	P/C	11.16	EPS next 5Y	3.50%	ROE	24.69%	52W High	381.52 -6.36%	Perf Year	35.37%
Cash/sh	32.02	P/FCF	18.50	EPS past 3/5Y	35.84% 21.10%	ROIC	17.92%	52W Low	243.23 46.88%	Perf 3Y	35.73%
Dividend Est.	44.00 (12.32%)	EV/EBITDA	10.15	Sales past 3/5Y	22.68% 14.36%	Gross Margin	51.03%	Volatility	2.51% 2.64%	Perf 5Y	112.88%
Dividend TTM	33.26 (9.31%)	EV/Sales	5.88	EPS Y/Y TTM	-21.18%	Oper. Margin	50.00%	ATR (14)	10.32	Perf 10Y	185.89%
Dividend Ex-Date	Nov 26, 2025	Quick Ratio	2.67	Sales Y/Y TTM	8.65%	Profit Margin	31.48%	RSI (14)	49.58	Recom	2.06
Dividend Gr. 3/5Y	77.47% -	Current Ratio	2.69	EPS Q/Q	-36.46%	SMA20	-2.03%	Beta	0.50	Target Price	377.71
Payout	93.91%	Debt/Eq	0.58	Sales Q/Q	19.00%	SMA50	4.84%	Rel Volume	1.58	Prev Close	363.66
Employees	1936	LT Debt/Eq	0.57	Earnings	Oct 22 AMC	SMA200	11.91%	Avg Volume	53.43K	Price	357.26
IPO	Sep 28, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-25.75% 10.01%	Trades		Volume	32,735	Change	-1.76%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Nov-14-25	Downgrade	JP Morgan	Overweight → Neutral
Nov-10-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$300
May-19-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-13-24	Downgrade	Barclays	Overweight → Equal Weight
Dec-14-23	Upgrade	BofA Securities	Underperform → Buy
Nov-28-23	Downgrade	Citigroup	Neutral → Sell	$228 → $222
Oct-24-23	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jul-11-23	Downgrade	Goldman	Neutral → Sell	$28
May-22-23	Upgrade	Barclays	Underweight → Overweight
Mar-30-23	Downgrade	JP Morgan	Overweight → Neutral	$520 → $595
Aug-08-22	Upgrade	JP Morgan	Neutral → Overweight
Dec-01-21	Upgrade	Goldman	Sell → Neutral	$179 → $225
Jun-15-21	Upgrade	Scotiabank	Sector Underperform → Sector Perform	$204
Apr-12-21	Downgrade	Goldman	Neutral → Sell	$135 → $165
Mar-11-21	Downgrade	UBS	Buy → Neutral
Oct-06-20	Downgrade	Citigroup	Buy → Neutral
Oct-01-20	Downgrade	Goldman	Buy → Neutral
Sep-14-20	Upgrade	Scotiabank	Sector Underperform → Sector Perform
Apr-16-20	Upgrade	HSBC Securities	Reduce → Hold

Show Previous Ratings

Feb-13-26 09:40AM	Are Transportation Stocks Lagging Grupo Aeroportuario del Sureste (ASR) This Year? (Zacks)
Feb-09-26 04:30PM	ASUR Announces Total Passenger Traffic for January 2026 (PR Newswire)
Jan-29-26 09:55AM	Grupo Aeroportuario del Sureste (ASR) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-28-26 04:57PM	Bank Profits Rise Amid Credit Card Uncertainty (Motley Fool)
Jan-26-26 04:30PM	ASUR Announces Resolutions Approved at the General Ordinary Shareholders' Meeting held on January 26th, 2026 (PR Newswire)
01:03PM	Loading…
Jan-15-26 01:03PM	Grupo Aeroportuario del Sureste, S. A. B. de C. V. (ASR): A Bull Case Theory (Insider Monkey)
Jan-06-26 04:30PM	ASUR Announces Total Passenger Traffic for December 2025 (PR Newswire)
Dec-11-25 04:30PM	ASUR Completes Acquisition of URW Airports, Expanding to Major U.S. Airport Hubs (PR Newswire)
Dec-08-25 04:30PM	ASUR Announces Total Passenger Traffic for November 2025 (PR Newswire)
Dec-04-25 05:02PM	ASUR Calls for a Shareholders' Meeting (PR Newswire)
Nov-18-25 05:42PM	ASUR SIGNS DEAL TO ACQUIRE MOTIVA'S STAKE IN AIRPORT BUSINESS IN BRAZIL, ECUADOR, COSTA RICA AND CURACAO (PR Newswire)
Nov-06-25 04:30PM	ASUR Announces Total Passenger Traffic for October 2025 (PR Newswire)
11:40AM	ZTO or ASR: Which Is the Better Value Stock Right Now? (Zacks)
Nov-05-25 12:00PM	ASUR Announces at the request of the Mexican Stock Exchange ("BMV") (PR Newswire)
Oct-22-25 04:30PM	ASUR ANNOUNCES 3Q25 RESULTS (PR Newswire)
04:25PM	Loading…
04:25PM	Grupo Aeroportuario del Sureste, S. A. B. de C. V. (ASR): A Bull Case Theory (Insider Monkey)
Oct-21-25 11:40AM	ZTO or ASR: Which Is the Better Value Stock Right Now? (Zacks)
Oct-06-25 04:30PM	ASUR Announces Total Passenger Traffic for September 2025 (PR Newswire)
Sep-25-25 12:24PM	Market Cap Game Show: Planes, Steaks & Automobiles (Motley Fool)
Sep-09-25 01:09AM	What Does Wall Street Think About Grupo Aeroportuario del Sureste (ASR)? (Insider Monkey)
Sep-08-25 04:30PM	ASUR Announces Total Passenger Traffic for August 2025 (PR Newswire)
Aug-27-25 12:22AM	Grupo Aeroportuario dl Sureste SAB CV (ASR) Capitalizing on Robust Passenger Traffic in Latin America (Insider Monkey)
Aug-05-25 04:30PM	ASUR Announces Total Passenger Traffic for July 2025 (PR Newswire)
Jul-30-25 07:00PM	ASUR SIGNS DEAL TO ACQUIRE URW'S AIRPORT RETAIL CONCESSIONS AT KEY TERMINALS AT NEW YORK JFK, LOS ANGELES LAX, AND CHICAGO ORD AIRPORTS (PR Newswire)
Jul-24-25 05:00PM	Grupo Aeroportuario del Sureste SAB de CV (ASR) Q2 2025 Earnings Call Highlights: Strong ... (GuruFocus.com)
Jul-22-25 04:35PM	ASUR ANNOUNCES 2Q25 RESULTS (PR Newswire)
Jul-11-25 09:40AM	Is Grupo Aeroportuario del Sureste (ASR) Stock Outpacing Its Transportation Peers This Year? (Zacks)
Jul-07-25 04:30PM	ASUR Announces Total Passenger Traffic for June 2025 (PR Newswire)
Jun-26-25 04:32AM	Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB (Zacks)
Jun-25-25 07:51AM	5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility (Zacks)
09:40AM	Loading…
Jun-24-25 09:40AM	Are Business Services Stocks Lagging GORILLA TECH GP (GRRR) This Year? (Zacks)
09:40AM	Is Air Lease (AL) Stock Outpacing Its Transportation Peers This Year? (Zacks)
Jun-23-25 09:35AM	After Plunging 13% in 4 Weeks, Here's Why the Trend Might Reverse for Grupo Aeroportuario del Sureste (ASR) (Zacks)
08:21AM	Best Momentum Stock to Buy for June 23rd (Zacks)
Jun-05-25 04:30PM	ASUR Announces Total Passenger Traffic for May 2025 (PR Newswire)
Jun-04-25 09:10AM	Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks (Zacks)
May-29-25 09:10AM	3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income (Zacks)
May-23-25 09:10AM	3 Top Dividend Stocks to Maximize Your Retirement Income (Zacks)
May-07-25 11:40AM	DHLGY or ASR: Which Is the Better Value Stock Right Now? (Zacks)
May-05-25 04:30PM	ASUR Announces Total Passenger Traffic for April 2025 (PR Newswire)
May-02-25 06:45PM	ASR: Growth Engines Firing In Colombia And Puerto Rico - A Compelling Opportunity (Seeking Alpha)
Apr-24-25 03:05AM	Grupo Aeroportuario del Sureste SAB de CV (ASR) Q1 2025 Earnings Call Highlights: Strong ... (GuruFocus.com)
Apr-23-25 06:13PM	ASUR Announces Resolutions Approved at the General Annual Ordinary Shareholders' Meeting held on April 23rd, 2025 (PR Newswire) +5.72%
03:31PM	Grupo Aeroportuario del Sureste, S. A. B. de C. V. (ASR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
Apr-22-25 04:47PM	Grupo Aeroportuario del Sureste: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	ASUR ANNOUNCES 1Q25 RESULTS (PR Newswire)
Apr-10-25 04:30PM	ASUR Files its 2024 Form 20-F with the U.S. Securities and Exchange Commission and Publishes its 2024 Sustainability Report (PR Newswire)
Apr-07-25 04:30PM	ASUR Announces Total Passenger Traffic for March 2025 (PR Newswire)
Mar-17-25 03:31AM	Grupo Aeroportuario del Sureste (ASR) Soars 10.6%: Is Further Upside Left in the Stock? (Zacks)
Mar-13-25 04:30PM	ASUR Calls for a Shareholders' Meeting (PR Newswire) +10.62%
Mar-05-25 04:15PM	ASUR Announces Total Passenger Traffic for February 2025 (PR Newswire)
Feb-24-25 05:41PM	Grupo Aeroportuario del Sureste: Q4 Earnings Snapshot (Associated Press Finance)
04:30PM	ASUR ANNOUNCES 4Q24 RESULTS (PR Newswire)
Feb-17-25 02:08AM	Grupo Aeroportuario del Sureste (ASR): Among the Best Airport Stocks to Invest in Now (Insider Monkey)
Feb-06-25 04:30PM	ASUR Announces Total Passenger Traffic for January 2025 (PR Newswire)
Jan-08-25 06:27AM	ASUR Reports Mixed Passenger Traffic Growth in December 2024 (TipRanks)
Jan-06-25 04:30PM	ASUR Announces Total Passenger Traffic for December 2024 (PR Newswire)
Dec-05-24 04:30PM	ASUR Announces Total Passenger Traffic for November 2024 (PR Newswire)
Nov-05-24 04:30PM	ASUR Announces Total Passenger Traffic for October 2024 (PR Newswire)
Oct-24-24 06:28AM	ASUR Reports Revenue Growth Amid Passenger Traffic Dip (TipRanks)
Oct-22-24 05:17PM	Grupo Aeroportuario del Sureste: Q3 Earnings Snapshot (Associated Press Finance)
04:30PM	ASUR ANNOUNCES 3Q24 RESULTS (PR Newswire)
Oct-09-24 03:10PM	Grupo Aeroportuario del Sureste SAB de CV (ASR) Q2 2024 Earnings Call Highlights: Record ... (GuruFocus.com)
Oct-07-24 04:30PM	ASUR Announces Total Passenger Traffic for September 2024 (PR Newswire)
Sep-30-24 01:39PM	Is Grupo Aeroportuario del Sureste, S. A. B. de C. V. (ASR) One of the Worst Airport Stocks to Buy? (Insider Monkey)
Sep-23-24 09:34PM	Is Grupo Aeroportuario del Sureste SAB de CV (ASR) a Good Airport Stock To Add To Your Portfolio? (Insider Monkey)
Sep-05-24 04:30PM	ASUR Announces Total Passenger Traffic for August 2024 (PR Newswire)
Aug-05-24 04:30PM	ASUR Announces Total Passenger Traffic for July 2024 (PR Newswire)
Jul-30-24 07:25AM	The 3 Best Latin American Stocks to Buy Now (InvestorPlace)
Jul-23-24 05:29PM	Grupo Aeroportuario del Sureste: Q2 Earnings Snapshot (Associated Press Finance)
04:30PM	ASUR ANNOUNCES 2Q24 RESULTS (PR Newswire)
Jul-08-24 04:30PM	ASUR Announces Total Passenger Traffic for June 2024 (PR Newswire)
Jun-07-24 03:29PM	ASUR Announces Total Passenger Traffic for May 2024 (PR Newswire) -5.32%
03:29PM	/C O R R E C T I O N -- Grupo Aeroportuario del Sureste, S.A.B. de C.V./ (PR Newswire)
May-24-24 07:02AM	Grupo Aeroportuario del Sureste SAB de CV's Dividend Analysis (GuruFocus.com)
May-06-24 04:30PM	ASUR Announces Total Passenger Traffic for April 2024 (PR Newswire)
Apr-30-24 09:40AM	Is Grupo Aeroportuario del Sureste (ASR) Outperforming Other Transportation Stocks This Year? (Zacks)
Apr-24-24 01:21PM	ASUR Announces Resolutions Approved at the General Annual Ordinary Shareholders' Meeting held on April 24th, 2024 (PR Newswire)
10:49AM	Grupo Aeroportuario del Sureste, S. A. B. de C. V. (NYSE:ASR) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-22-24 05:15PM	Grupo Aeroportuario del Sureste Q1 EPS, Revenue Increase (MT Newswires) +7.33%
04:51PM	Grupo Aeroportuario del Sureste: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	ASUR Reports 1Q24 Financial Results (PR Newswire)
Apr-15-24 05:00PM	ASUR Files Form 20-F 2023 with the U.S. Securities and Exchange Commissionand Publishes Sustainability Report 2023 (PR Newswire)
Apr-12-24 03:00PM	Wall Street Favorites: 3 Travel Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
Apr-08-24 04:30PM	ASUR Announces Total Passenger Traffic for March 2024 (PR Newswire)
Mar-07-24 04:30PM	ASUR Calls for a Shareholders' Meeting (PR Newswire)
Mar-06-24 04:30PM	ASUR Announces Total Passenger Traffic for February 2024 (PR Newswire)
Feb-29-24 08:10AM	Grupo Aeroportuario del Sureste, S. A. B. de C. V. (NYSE:ASR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-26-24 07:51PM	Grupo Aeroportuario del Sureste: Q4 Earnings Snapshot (Associated Press Finance)
04:30PM	ASUR Reports 4Q23 Financial Results (PR Newswire)
Feb-14-24 09:40AM	Has Grupo Aeroportuario del Sureste (ASR) Outpaced Other Transportation Stocks This Year? (Zacks)
Feb-06-24 04:30PM	ASUR Announces Total Passenger Traffic for January 2024 (PR Newswire)
Jan-04-24 04:30PM	ASUR Announces Total Passenger Traffic for December 2023 (PR Newswire)
Dec-13-23 04:30PM	ASUR Announces Approval of its 2024-2028 Investment Plan Totaling Ps.28.5 billion Expressed in Currency as of December 2022 (PR Newswire) +26.06%
Dec-06-23 04:30PM	ASUR Announces Total Passenger Traffic for November 2023 (PR Newswire)
Nov-06-23 04:30PM	ASUR Announces Total Passenger Traffic for October 2023 (PR Newswire)
Oct-25-23 11:15AM	Grupo Aeroportuario del Sureste, S. A. B. de C. V. (NYSE:ASR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-23-23 05:51PM	Grupo Aeroportuario del Sureste: Q3 Earnings Snapshot (Associated Press Finance)
05:30PM	ASUR Reports 3Q23 Financial Results (PR Newswire)
Oct-19-23 05:20PM	ASUR ANNOUNCES UPDATES ON GOVERNMENT ACTION TO AMEND THE TARIFF BASE REGULATION (PR Newswire)

Grupo Aeroportuario del Sureste SA de CV is a holding company, which engages in the operation, maintenance, and development of airports It operates through the following segments: Cancun, Aerostar, Airplan, Villahermosa, Merida, Holding and Services, and Other. The company was founded in 1996 and is headquartered in Mexico City, Mexico.

Open in Screener

OMER

Omeros Corporation

Feb 24 • 11:49AM ET

11.68

+0.24 2.09 %

Healthcare • Biotechnology • USA • NASD

OMER Omeros Corporation daily Stock Chart

Peers: IONS BMRN NBIX INCY SRPT EXEL GILD VRTX REGN AMGN

| Held by: VTI IWM VXF IWO SCHA VTWO XPH VHT IHE IWC

Index	RUT	P/E	-	EPS (ttm)	-2.02	Insider Own	3.78%	Shs Outstand	70.07M	Perf Week	-2.10%
Market Cap	828.06M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-2.19%	Shs Float	68.22M	Perf Month	-2.10%
Enterprise Value	1.16B	PEG	-	EPS next Q	-0.57	Inst Own	45.73%	Short Float	25.89%	Perf Quarter	41.91%
Income	-121.16M	P/S	-	EPS this Y	24.72%	Inst Trans	0.11%	Short Ratio	7.37	Perf Half Y	165.44%
Sales	0.00M	P/B	-	EPS next Y	73.73%	ROA	-48.59%	Short Interest	17.66M	Perf YTD	-32.00%
Book/sh	-3.15	P/C	22.94	EPS next 5Y	-	ROE	-	52W High	17.65 -33.83%	Perf Year	34.55%
Cash/sh	0.51	P/FCF	-	EPS past 3/5Y	-14.69% -9.58%	ROIC	-120.62%	52W Low	2.95 295.91%	Perf 3Y	208.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.81% 5.41%	Perf 5Y	-48.07%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	12.32%	Oper. Margin	-	ATR (14)	0.73	Perf 10Y	13.94%
Dividend Ex-Date	-	Quick Ratio	0.89	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.82	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	0.89	EPS Q/Q	16.11%	SMA20	0.33%	Beta	2.46	Target Price	43.67
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-3.82%	Rel Volume	0.36	Prev Close	11.44
Employees	202	LT Debt/Eq	-	Earnings	Nov 13 AMC	SMA200	70.01%	Avg Volume	2.40M	Price	11.68
IPO	Oct 08, 2009	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.19% -	Trades		Volume	331,088	Change	2.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-25	Initiated	H.C. Wainwright	Buy	$9
Dec-23-24	Initiated	D. Boral Capital	Buy	$36
Nov-14-24	Initiated	Rodman & Renshaw	Buy	$9
Dec-08-22	Downgrade	UBS	Buy → Neutral	$12 → $2
Nov-08-22	Downgrade	BofA Securities	Neutral → Underperform	$8 → $3
Jun-08-22	Downgrade	BofA Securities	Buy → Neutral	$12 → $4
Oct-08-21	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-21	Downgrade	Wedbush	Neutral → Underperform
Oct-01-21	Downgrade	Maxim Group	Buy → Hold
Sep-27-21	Initiated	JP Morgan	Neutral	$15
Feb-01-21	Initiated	UBS	Buy	$25
Oct-20-20	Initiated	BofA Securities	Buy	$21
Aug-21-20	Reiterated	H.C. Wainwright	Buy	$34 → $32
Aug-14-20	Reiterated	Maxim Group	Buy	$25 → $20
May-06-19	Initiated	Cantor Fitzgerald	Overweight	$26
Jul-12-18	Initiated	Seaport Global Securities	Buy	$30
Mar-23-18	Downgrade	Wedbush	Outperform → Neutral	$47 → $19
Mar-05-18	Downgrade	Needham	Buy → Hold
Nov-08-17	Initiated	H.C. Wainwright	Buy	$30
May-11-17	Downgrade	Cantor Fitzgerald	Buy → Neutral	$21 → $15

Show Previous Ratings

Feb-17-26 08:45AM	Omeros Announces Successful Primate Study in OncotoX-AML Drug Program (Business Wire)
Jan-27-26 09:00AM	Omeros Announces First Commercial Sales of YARTEMLEA (Business Wire) +9.89%
Dec-29-25 10:57AM	Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA (Zacks) +5.47%
Dec-26-25 06:36PM	Omeros Announces New Date for YARTEMLEA Approval Conference Call (Business Wire)
Dec-24-25 05:42PM	Why Omeros Stock Skyrocketed Today (Motley Fool) +75.54%
09:00AM	Loading…
09:00AM	FDA Approves Omeros' YARTEMLEA - First and Only Therapy Indicated for TA-TMA (Business Wire)
Dec-10-25 02:15PM	Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz (Insider Monkey)
Dec-08-25 08:24AM	Do You Believe Omeros Corporation's (OMER) New Monoclonal Antibody Has Strong Chances of Approval? (Insider Monkey) +5.07%
Dec-01-25 08:30AM	Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) (Business Wire)
Nov-14-25 12:02AM	Omeros Corp (OMER) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges (GuruFocus.com) +25.32%
Nov-13-25 05:33PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance) -8.85%
04:11PM	Omeros Corporation Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-11-25 08:30AM	Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 (Business Wire)
Oct-26-25 06:05AM	Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential? (Insider Monkey)
Oct-23-25 08:16AM	Breakout Momentum Plays You Need to Know About (MarketBeat)
07:41AM	Loading…
Oct-22-25 07:41AM	Omeros Sells Exclusive Global Rights for Drug Zaltenibart to Novo Nordisk (Insider Monkey)
Oct-16-25 12:16PM	Novo Nordisk snaps up Omeros rare disease asset for up to $2.1bn (Pharmaceutical Technology) -5.66%
11:10AM	NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio (Zacks)
08:30AM	Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group (Business Wire)
03:39AM	A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? (Motley Fool)
Oct-15-25 04:12PM	Omeros Catapults 154% On A Surprise $2.1 Billion Deal With Novo Nordisk (Investor's Business Daily) +154.15%
03:58PM	Novo Nordisk Just Signed a Key Drug Deal With Omeros. Is There Any Room Left for OMER Stock to Run? (Barchart)
12:49PM	Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk (Investor's Business Daily)
11:25AM	Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion (The Wall Street Journal)
10:52AM	Novo wagers up to $2.1B on Omeros rare disease drug (BioPharma Dive)
09:17AM	Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug (The Wall Street Journal)
Sep-02-25 08:45AM	Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program (Business Wire)
Aug-15-25 03:24AM	Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... (GuruFocus.com) +7.04%
Aug-14-25 04:08PM	Omeros: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Second Quarter 2025 Financial Results (Business Wire)
04:02PM	Loading…
Aug-11-25 04:02PM	Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 (Business Wire)
Jul-25-25 08:00AM	Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering (Business Wire) +6.69%
Jun-27-25 08:30AM	Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA (Business Wire)
Jun-24-25 08:30AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) +5.96%
Jun-03-25 09:35AM	Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER) (Zacks)
May-16-25 08:13AM	Q1 2025 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) -18.61%
03:13AM	Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... (GuruFocus.com)
May-15-25 04:34PM	Omeros: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Omeros Corporation Reports First Quarter 2025 Financial Results (Business Wire)
May-12-25 05:05PM	Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025 (Business Wire) -38.59% +16.73%
08:41AM	Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 (Business Wire)
May-06-25 09:16AM	FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date (Business Wire) -6.90%
Apr-10-25 09:10AM	Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros Proprietary OncotoX-AML Clinical Program (Business Wire) -9.85%
Apr-08-25 09:00AM	Omeros Corporation To Introduce Its Proprietary T-CAT Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases (Business Wire) -12.55%
Apr-01-25 09:27AM	Q4 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... (GuruFocus.com)
Mar-31-25 08:57PM	Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:17PM	Omeros: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results (Business Wire)
Mar-26-25 09:15AM	Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 (Business Wire) -6.99%
Mar-24-25 07:58AM	Omeros to activate site for Phase III programme of zaltenibart for PNH (Clinical Trials Arena)
Mar-21-25 09:15AM	Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program (Business Wire)
Mar-13-25 09:00AM	Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Companys OMS527 Program to Treat Cocaine Use Disorder (Business Wire)
Feb-21-25 09:21AM	Omeros announces results for narsoplimab expanded access program (TipRanks)
Feb-20-25 09:10AM	Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA (Business Wire)
Feb-14-25 09:00AM	Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings (Business Wire)
Feb-10-25 09:00AM	Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program (Business Wire)
Jan-16-25 09:15AM	Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint (Business Wire)
Dec-19-24 10:46AM	Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges (GuruFocus.com) +37.27%
09:15AM	Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint - Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA (Business Wire)
Dec-10-24 12:22PM	Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges (Insider Monkey) -7.38%
08:45AM	Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting (Business Wire)
Dec-02-24 08:45AM	Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting (Business Wire) +5.29%
Nov-22-24 02:31PM	Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News (GuruFocus.com) +41.14%
Nov-21-24 09:15AM	Omeros Corporation Provides Update on Progress Toward BLA Resubmission (Business Wire) +28.19%
Nov-14-24 02:01PM	Q3 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) +65.87%
02:15AM	Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments (GuruFocus.com)
Nov-13-24 04:17PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-11-24 04:11PM	Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024 (Business Wire)
Oct-24-24 08:45AM	FDA Grants Rare Pediatric Disease Designation to Omeros MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy (Business Wire)
Aug-07-24 05:16PM	Omeros: Q2 Earnings Snapshot (Associated Press Finance) -5.03% -5.78%
04:02PM	Omeros Corporation Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 04:02PM	Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 (Business Wire) -10.68%
Jun-04-24 09:00AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) -6.16%
Jun-03-24 09:00AM	Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 (Business Wire) +20.83%
May-16-24 01:10PM	Q1 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) -20.62%
03:10AM	Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ... (GuruFocus.com)
May-15-24 08:55PM	OMER Stock Earnings: Omeros Misses EPS for Q1 2024 (InvestorPlace)
04:11PM	Omeros: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports First Quarter 2024 Financial Results (Business Wire)
May-10-24 08:50AM	Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 (Business Wire)
May-09-24 08:50AM	Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
Apr-02-24 12:41PM	Q4 2023 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
11:22AM	Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-01-24 09:53PM	OMER Stock Earnings: Omeros Misses EPS for Q4 2023 (InvestorPlace) -7.54%
05:32PM	Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results (GuruFocus.com)
04:17PM	Omeros: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results (Business Wire)
Mar-27-24 08:30AM	Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 (Business Wire)
Mar-17-24 10:02AM	Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade (InvestorPlace)
Feb-20-24 09:00AM	Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (Business Wire)
Feb-07-24 09:34AM	3 Sleeper Stocks Under $15 Ready to Explode by 2029 (InvestorPlace)
Feb-01-24 09:11AM	Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust (Business Wire)
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Nov-11-23 03:01PM	Omeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 09:43AM	Q3 2023 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 04:33PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 08:00AM	Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023 (Business Wire) +6.25%

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Demopulos Gregory A MD	Chairman, CEO & President	Feb 18 '26	Option Exercise	10.27	400,000	4,108,000	1,826,986	Feb 20 09:40 PM
Borges David J.	VP, Finance & CAO	Jan 13 '26	Option Exercise	3.06	30,000	91,800	30,000	Jan 14 05:25 PM
Borges David J.	VP, Finance & CAO	Jan 12 '26	Sale	12.72	30,000	381,600	0	Jan 14 05:25 PM
Borges David J.	VP, Finance & CAO	Jan 13 '26	Sale	12.31	30,000	369,315	0	Jan 14 05:25 PM
DAVID J BORGES	Officer	Jan 13 '26	Proposed Sale	12.31	30,000	369,315		Jan 13 04:31 PM
DAVID J BORGES	Officer	Jan 12 '26	Proposed Sale	12.72	30,000	381,600		Jan 12 04:32 PM

ALNY

Alnylam Pharmaceuticals Inc

ASR

Grupo Aeroportuario Del Sureste S.A. ADR

OMER

Omeros Corporation

Upgrade your FINVIZ experience